ISPOR Europe 2022 Vienna

Share on:

Sunday, November 6 - Wednesday, November 9, 2022

Conference Website

ISPOR Europe 2022 Exhibitor badge

If you are looking for ISPOREU 2023, click here.

We're looking forward to seeing you live and in person at ISPOR in Vienna! We invite you to stop by our booth, X2-107, to say hello and register for our fantastic textbook giveaway (six different books). If you're interested in learning more about any of the science we're presenting, please reach out to our researchers using the links below.

See our contributions

Meet our researchers

See the books we're giving away

Schedule of RTI Health Solutions Contributions

Presentations | Times within the program are in Central European Time (CET)

November 7 - 7:15

Special Interest Group

ISPOR Oncology SIG Open Meeting

Co-presenter: Sorrel Wolowacz

November 7 - 10:15

Podium Session 110

Incorporating informal care considerations in HTA

Moderator: Sorrel Wolowacz

November 8 - 10:15

Issue Panel

Clinical evidence for health technology assessment in oncology, are we going backwards? Where are we going with single-arm trials? Wolowacz S, Bhatnagar V, Vickers A, Pickaert AP.

November 8 - 11:45

Discussion Group

Clinical evidence for health technology assessment in oncology, are we going backwards? Where are we going with single-arm trials? Wolowacz S, Bhatnagar V, Vickers A, Pickaert AP.

Panel: Sorrel Wolowacz, Min-Hua Jen, and Adrian Vickers

November 8 - 13:30

Podium Session 227

Does the choice of cost-effectiveness model approach matter?

Moderator: Thor-Henrik Brodtkorb

13:45 - P37: Impact of method for modelling Distant Recurrence (DR) on Cost-Effectiveness (CE) of Nivolumab (NIVO) as an adjuvant treatment of Muscle-Invasive Urothelial Carcinoma (MIUC) patients with high risk of recurrence in France. Bonastre J, Negrier S, Colrat F, Chamielec C, Teitsson S, Knight C, Ni L, Chevalier J, Gaudin AF, Roupret M, Branchoux S.

Poster Session 1 | November 7 | 10:00-13:15

CO13

Evidence gap analysis of the burden of illness and treatment of primary immune thrombocytopenia. doi: 10.1016/j.jval.2022.09.094Yang J, Masaquel C, Arvin-Berod C, Phillips G, Godar M, Desai M, Ayguasanosa J.

EE63

Economic burden of respiratory syncytial virus in adults in the United States. doi: 10.1016/j.jval.2022.09.315Carrico J, Hicks K, Panozzo CA, Ghaswalla P.

Economic Evaluation

HTA19

How are United States ICER'S evidence ratings determined?: A systematic review of ICER'S evidence ratings in evidence reports for new drugs in 2020 and 2021. doi: 10.1016/j.jval.2022.09.1479Ronquest N, Clinkscales M, Paret K.

Clinical Outcomes, Health Technology Assessment, Study Approaches
Presenting Author: Naoko Ronquest

HTA26

Health technology assessment (HTA) methods for monoclonal antibodies for treatment and prevention of COVID-19. doi: 10.1016/j.jval.2022.09.1486Warttig S, Ling C.

Health Policy & Regulatory

PCR29

A systematic literature review of utility estimates for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). doi: 10.1016/j.jval.2022.09.1964Yucel E, Hartley L, Bell J, Wolowacz S, Kamgar F, Hawe E.

Patient-Centered Research, Study Approaches
Judith Bell presenting

Poster Session 2 | November 7 | 15:00-18:15

EE184

Assessing the cost-effectiveness of the Novavax COVID-19 vaccine as a potential booster vaccine option for adults in the United States. doi: 10.1016/j.jval.2022.09.434Paret K, Beyhaghi H, Herring W, Rousculp M, Toback S, Mauskopf J.

Economic Evaluation, Study Approaches

EE201

Survival analysis methods used in immuno-oncology NICE appraisals. doi: 10.1016/j.jval.2022.09.451Hancock H, Brockbank J, Theodorou E, Brodtkorb TH.

Economic Evaluation, Methodological & Statistical Research

EE215

Pharmacoeconomic analysis of adjuvant nivolumab for patients with resected esophageal or gastroesophageal junction cancer in Switzerland. doi: 10.1016/j.jval.2022.09.464Oniangue-Ndza C, Strittmatter G, Lucas A, Wilson M, Kassahun S, Singh P.

Economic Evaluation

EE228

A review of treatment effect waning methods for immuno-oncology therapies in National Institute for Health and Care Excellence technology appraisals. doi: 10.1016/j.jval.2022.09.476Kamgar F, Ho S, Hawe E, Brodtkorb TH.

Methodological & Statistical Research, Study Approaches

EE234

Comparing the public health impact of a 15- or 20-valent pneumococcal conjugate vaccine pediatric national immunization program in Spain. doi: 10.1016/j.jval.2022.09.482Lopez A, del Amo M, Perdizet J, McDade C, Wilson M.

Economic Evaluation, Epidemiology & Public Health, Study Approaches

EPH50

The public health impact of routine vaccination in 16- to 40-year-old females for the prevention of cytomegalovirus and congenital cytomegalovirus in the United Kingdom. doi: 10.1016/j.jval.2022.09.972Zinan Y, Graham J, Diaz-Decaro J, Myers E, Lumley M, Buck P.

Epidemiology & Public Health, Methodological & Statistical Research, Study Approaches

MSR40

A comparison of the performance of a range of trial-level surrogacy methods. doi: 10.1016/j.jval.2022.09.1771Vickers A.

Clinical Outcomes, Methodological & Statistical Research

PCR97

Patient and caregiver insight into the impact of non-muscle-invasive bladder cancer and its treatments: a social media review. doi: 10.1016/j.jval.2022.09.2032Crawford R, Thompson A, Chang J, Morrison R, Doward L.

Patient-Centered Research

SA30

Evaluation of national approvals and data-collection durations in retrospective noninterventional medical record review studies conducted in the United States, Canada, Europe, and Asia. doi: 10.1016/j.jval.2022.09.2424Sluga-O'Callaghan M, Derrien Ansquer V, Frugier G, Houghton K.

Organizational Practices

Poster Session 3 | November 8 | 10:00-13:15

CO85

Evidence gap analysis of the burden of illness and treatment of chronic inflammatory demyelinating polyneuropathy. doi: 10.1016/j.jval.2022.09.164Fernandez M, Copley-Merriman C, Arvin-Berod C, Phillips G, Gelinas D, Weiss R, Hofman E, Tse A.

CO90

A systematic literature review of prognostic factors and surrogate endpoint analyses in chronic lymphocytic leukemia and small lymphocytic lymphoma. doi: 10.1016/j.jval.2022.09.169Yucel E, Lunan M, Hartley L, Ahdesmaki O, Bull R, Hawe E.

Clinical Outcomes, Study Approaches
Emma Hawe presenting

CO95

The relationship between Asthma Control Questionnaire scores and exacerbation risk, resource utilization, and utility values: an analysis from the CAPTAIN trial. doi: 10.1016/j.jval.2022.09.174Herring W, Shen Q, Zhang Y, Martin A, Otiker T, Zhang W.

Clinical Outcomes

EE322

Public health impact and return on investment of the pediatric immunization program in Poland. doi: 10.1016/j.jval.2022.09.568Mellott C, Jaworski R, Carrico J, Clinkscales M, Talbird S, Dobrowolska I, Golicki D, Tsoumani E, Sabale U.

Economic Evaluation

EE334

Cost-effectiveness analysis of nivolumab as an adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence in Greece. doi: 10.1016/j.jval.2022.09.580Ni L, Diamantogiannis F, Teitsson S, Knight C.

Economic Evaluation, Study Approaches

EE403

Health and economic impact of a novel 3-antigen vaccine for the prevention of hepatitis B in adults in Germany: a cost-effectiveness analysis. doi: 10.1016/j.jval.2022.09.649Talbird S, Graham J, Anderson S, Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F.

Economic Evaluation, Epidemiology & Public Health, Study Approaches
Sandra Talbird presenting

EE461

Cost-effectiveness of nivolumab as an adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence with tumor cell pd-l1 expression ≥ 1% in Denmark. doi: 10.1016/j.jval.2022.09.706Kamgar F, Thybo SH, Johannesen K, Teitsson S, Brodtkorb TH.

Economic Evaluation, Study Approaches

**Top 5% finalist**

EE526

Public health impact and cost-effectiveness of recombinant zoster vaccine for vaccinating immunocompromised adults against herpes zoster in the United States. doi: 10.1016/j.jval.2022.09.767Salem A, Curran D, Carrico J, La EM, Lorenc S, Hicks K, Poston S, Carpenter CF.

Economic Evaluation, Epidemiology & Public Health

PCR142

Adaptation of the urticaria patient daily diary for caregiver completion in pediatric chronic spontaneous urticaria. doi: 10.1016/j.jval.2022.09.2077Whalley D, Morrison R, Balp MM, Joubert Y, McKenna SJ, Christen L, Naujoks C, Gardner DD, Dery E, Lacombe A.

Patient-Centered Research

PCR144

International adaptation and linguistic validation of the hypoparathyroidism daily diary of symptom experience (HPT-DD-SE) and the hypoparathyroidism life impact questionnaire (HPT-LIQ). doi: 10.1016/j.jval.2022.09.2079Morrison R, Allas S, Crawford R, Tremel N, Weiss B, Robo C, Doward L.

Patient-Centered Research

PCR158

Patient reported outcomes (PRO) from phase 2 registrational trial of repotrectinib in patients with ROS1-positive advanced or metastatic non-small cell lung cancer (TRIDENT-1). doi: 10.1016/j.jval.2022.09.2093Shim A, Trone D, Reynolds M, Odom D, Sherif B, Stopatschinskaja S.

Methodological & Statistical Research, Organizational Practices, Patient-Centered Research, Study Approaches

Poster Session 4 | November 8 | 15:00-18:15

CO120

Evidence gap analysis of the burden of illness and treatment of pemphigus vulgaris and foliaceus. doi: 10.1016/j.jval.2022.09.198Copley-Merriman C, D'Souza V, Arvin-Berod C, Phillips G, Verheesen P, Heyerick A, Stoykov I.

EE462

Cost-effectiveness of nivolumab for the adjuvant treatment of muscle-invasive urothelial carcinoma patients with high risk of recurrence and tumor cell pd-l1 expression ≥ 1% in Sweden. doi: 10.1016/j.jval.2022.09.707Kamgar F, Johannesen K, Thybo SH, Teittson S, Brodtkorb TH.

Economic Evaluation, Study Approaches

EE463

Economic Evaluation, Study Approaches

EE469

A review of cure assumptions implemented in early-stage oncology NICE appraisals. doi: 10.1016/j.jval.2022.09.714Hancock H, Brockbank J, Brodtkorb TH, Lucherini S, Russell J.

Economic Evaluation, Methodological & Statistical Research

EE541

Cost-effectiveness and epidemiological impact of a novel 3-antigen vaccine for the prevention of Hepatitis B in adults in the United Kingdom. doi: 10.1016/j.jval.2022.09.782Talbird S, Graham J, Anderson S, Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F.

Economic Evaluation, Epidemiology & Public Health, Methodological & Statistical Research

**Top 5% finalist**

HSD73

HTA176

A systematic literature review of rationale, methods, and use of cost-effectiveness thresholds in health technology assessments. doi: 10.1016/j.jval.2022.09.1634Basarir H, Mauskopf J, McCrink L, Karmarkar T, O'Brien M.

Economic Evaluation, Health Technology Assessment, Study Approaches

HTA195

Analysis of health technology assessment (HTA) procedures and outcomes for orphan drugs. doi: 10.1016/j.jval.2022.09.1653Warttig S, D'Souza V.

Health Policy & Regulatory

PCR197

Psychometric evaluation of a new electronic pediatric asthma symptom diary. doi: 10.1016/j.jval.2022.09.2130Williams V, Romano (DeMuro) C, Clark M, Goss D, Naujoks C, Marvel J.

Patient-Centered Research

Poster Session 5 | November 9 | 9:00-12:30

EE591

Economic modeling considerations for rare neurodegenerative diseases of infancy and early childhood. doi: 10.1016/j.jval.2022.09.830Paret K, Ronquest N, Droege M.

Economic Evaluation, Methodological & Statistical Research, Study Approaches

EE615

Economic burden and quality of life in prurigo nodularis: a systematic literature review. doi: /10.1016/j.jval.2022.09.854Bahloul D, Tavi J, Thomas RB, Conlon S, Harold S, Moss E.

Economic Evaluation, Epidemiology & Public Health, Patient-Centered Research, Study Approaches

**Top 5% finalist**

EE622

Cost-effectiveness of Respiratory Syncytial Virus (RSV) prevention interventions in children: a model comparison study. doi: 10.1016/j.jval.2022.09.861Li X, Hodgson D, Flaig J, Kieffer A, Herring W, Beyhaghi H, Willem L, Jit M, Bilcke J, Beutels P.

Economic Evaluation, Study Approaches

HTA233

Analysis: first year of the new early access authorization in France. doi: 10.1016/j.jval.2022.09.1691D'Souza V, Copley-Merriman C.

Health Policy & Regulatory

MT41

Process and requirements for submitting nonpharmaceutical medical technologies to health technology assessment authorities. doi: 10.1016/j.jval.2022.09.1915Costello J, D'Souza V, Gildea L, Kinderås M, Ling C, Belisario JM, Warttig S.

Health Technology Assessment

How are United States ICER'S evidence ratings determined? A systematic review

Back to top

See who will be attending

any of our experts below to set up a time to meet and chat at ISPOR Europe.

Valerie Derrien Ansquer, MA

Director, Surveys and Observational Studies

Susan Barker, BA

Senior Director, Marketing-Digital Strategy

Hasan Basarir, PhD

Senior Director, Health Economics

Judith Bell, BSc

Senior Associate, Evidence Synthesis

James Brockbank, MSc

Director, Health Economics

Thor-Henrik Brodtkorb, PhD

Executive Director, Health Economics

Justin Carrico, MS

Associate Director, Health Economics

Rebecca Crawford, MA

Director, Patient-Centered Outcomes Assessment

Frank Distler, MSc

Senior Director, Business Development

Lynda Doward, MRes

VP, European Head Patient-Centered Outcomes Assessment

Vijay D'Souza, PhD

Associate Director, Market Access and Outcomes Strategy

Sydney Harold, MSc

Senior Research Associate, Evidence Synthesis

Head, Data Analytics and Design Strategy

William L Herring, PhD

Executive Director, Health Economics

Kelly Hollis, MBA

Vice President, Surveys and Observational Studies

Katie Houghton, MSc

Director, Health Economics

Maria Kinderas

Maria Kinderås, MSc

Associate Director, Market Access and Outcomes Strategy

Caroline Ling, PhD

Executive Director and HTA Specialist, Market Access and Outcomes Strategy

Carol Mansfield, PhD

Senior Economist and Head, Health Preference Assessment

Anubhav Nangia, MSc

Senior Statistician

Weyinmi Nuabor, MPH

Senior Associate, Market Access and Outcomes Strategy

Bolu Olowoyo, BSc

Associate Director, Business Development

Christine Poulos, PhD

Senior Economist and Vice President, Health Preference Assessment

Naoko Ronquest, PhD

Executive Director, US HTA Strategy and Early Modeling

Bintu Sherif, MS

Director, Biostatistics

Evangelia Simou

Evangelia Simou, PhD

Senior Statistician

Martina Sluga-O'Callaghan, PhD

Director, Surveys and Observational Studies

Sandra Talbird, MSPH

Executive Director, Health Economics

Adrian Vickers, PhD

Senior Director, Evidence Synthesis and Statistics

Diane Whalley, PhD

Executive Director, Patient-Centered Outcomes Assessment

Michele Wilson, PhD

Senior Director, Health Economics

Peter Wirth, BS

Vice President, Business Development

Sorrel Wolowacz, PhD

Head, European Health Economics

See the books we're giving away

We'll be giving away 6 different books coauthored by our researchers. Stop by booth X2-107 during ISPOR to register.

Back to top

Essentials of Pharmacoeconomics book cover

Essentials of Pharmacoeconomics: Health Economics and Outcomes Research
Coauthors: Josephine Mauskopf and Stephanie Earnshaw

Budget-Impact Analysis of Health Care Interventions

Budget Impact Analysis: A Practical Guide
Coauthors: Josephine Mauskopf, Stephanie Earnshaw, Anita Brogan, Sorrel Wolowacz, Thor-Henrick Broadkorb

Pharmacoeconomics book cover

Pharmacoeconomics: From Theory to Practice
Coauthor: Josephine Mauskopf

Oncology clinical trials book cover

Oncology Clinical Trials: Successful Design, Conduct, and Analysis
Coauthor: Ari Gnanasakthy

Artificial Intelligence for Healthcare

Artificial Intelligence for Healthcare: Interdisciplinary Partnerships for Analytics-Driven Improvements in a Post-COVID World
Coauthor: Christine Barnett

Pragmatic randomized clinical trials: using primary data collection and electronic health records

Pragmatic Randomized Clinical Trials: Using Primary Data Collection and Electronic Health Records
Coauthor: Kati Copley-Merriman and Margaret Mordin